Abstract
Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.
MeSH terms
-
Advisory Committees
-
Australia
-
Confidentiality
-
Cost-Benefit Analysis
-
Decision Making, Organizational
-
Drug Approval
-
Drug Costs*
-
Financing, Government*
-
Health Services Accessibility / economics*
-
Humans
-
Insurance, Pharmaceutical Services / economics*
-
Pharmacogenetics*